Showing 4251-4260 of 5623 results for "".
- GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of Lumevoq Vector DNA in Contralateral Eyes After Unilateral Injectionhttps://modernod.com/news/gensight-biologics-announces-publication-of-non-human-primate-study-reporting-presence-of-lumevoq-vector-dna-in-contralateral-eyes-after-unilateral-injection/2480491/GenSight Biologics announced that the journal "Molecular Therapy – Methods and Clinical Development" has published the results of a mechanistic study demonstrating the transfer of Lumevoq vector DNA from the injected eyes to the non-injected eyes of non-human prim
- Notal Vision Monitoring Center Reports AI Analysis of 10 Million ForeseeHome AMD Home Monitoring Testshttps://modernod.com/news/notal-vision-monitoring-center-reports-ai-analysis-of-10-million-foreseehome-amd-home-monitoring-tests/2480482/The Notal Vision Monitoring Center celebrates the artificial intelligence (AI) based analysis of the ten millionth test performed by over 20,000 patients with the FDA-cleared ForeseeHome devic
- Inspecs Acquires Hardy Amies Brandhttps://modernod.com/news/inspecs-acquires-hardy-amies-brand/2480476/Inspecs, a designer, manufacturer and distributor of eyewear frames and lenses, has announced the acquisition of the Hardy Amies brand, including all global intellectual property rights. Terms of the deal were not disclosed. Hardy Amies was founded by Sir Hardy Amie
- Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europehttps://modernod.com/news/nicox-is-granted-patent-for-blepharitis-product-candidate-ncx-4251-in-europe/2480459/Nicox SA announced that patent EP 3,769,753, expiring in 2040 and covering the company’s product candidate in development for blepharitis, NCX 4251, has been issued by the European Patent Office (EPO). The patent covers ophthalmic suspensions comprising a specific form of fluticas
- Edenlux Launches Campaign for Otus Personal EYE-Trainerhttps://modernod.com/news/edenlux-launches-campaign-for-otus-personal-eye-trainer/2480458/The Otus personal eye-trainer, which was created by Edenlux, has launched a campaign through Indiegogo. The device uses training called Vision Therapy to relieve the stress of the eyes. Vision Therapy is an exercise that repeats the contraction and relaxation of the
- jCyte Identifies Key Anatomical Biomarker Predictive of Substantial Restoration of Visual Function in Retinitis Pigmentosa Patients Treated With jCell Therapyhttps://modernod.com/news/jcyte-identifies-key-anatomical-biomarker-predictive-of-substantial-restoration-of-visual-function-in-retinitis-pigmentosa-patients-treated-with-jcell-therapy/2480452/jCyte announced key findings presented at AAO 2021 which demonstrated that retinitis pigmentosa (RP) patients with a baseline central visual field diameter greater than 20 degrees had a profound response to jCell treatment in its phase 2b study, the largest randomized clinical trial ever con
- Spherix Global Insights Introduces Ophthalmology to Suite of Independent Market Research and Intelligence Serviceshttps://modernod.com/news/spherix-global-insights-introduces-ophthalmology-to-suite-of-independent-market-research-and-intelligence-services/2480450/Spherix Global Insights, a market research firm providing independent coverage of select specialty markets, officially cut the ribbon on their ophthalmology franchise. Spherix derives actionable insights from its frequent, commercially-focused, primary market research, which i
- Kala Pharmaceuticals Acquires Combangio, Maker of Regenerative Biotherapies for Severe Ocular Surface Diseaseshttps://modernod.com/news/kala-pharmaceuticals-acquires-combangio-maker-of-regenerative-biotherapies-for-severe-ocular-surface-diseases/2480449/Kala Pharmaceuticals announced that it has acquired Combangio, a private, clinical-stage company developing regenerative biotherapies for severe ocular surface diseases. Combangio is developing CMB-012, a novel investigational secretome therapy, now known as KPI-012, to address the complex w
- Oculis Announces Patient Dosing in its First Phase 3 Study With OCS-01 Investigational Topical Eye Drop for DMEhttps://modernod.com/news/oculis-announces-patient-dosing-in-its-first-phase-3-study-with-ocs-01-investigational-topical-eye-drop-for-dme/2480432/Oculis SA announced that the first patients have been dosed in its phase 3 DIAMOND trial evaluating the efficacy and safety of OCS-01 in diabetic macular edema (DME). OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone (DSN
- Opus Genetics Announces Agreement with Massachusetts Eye and Ear and Harvard Medical School to License Third Program for Inherited Retinal Diseasehttps://modernod.com/news/opus-genetics-announces-agreement-with-massachusetts-eye-and-ear-and-harvard-medical-school-to-license-third-program-for-inherited-retinal-disease/2480431/Opus Genetics, a gene therapy company developing treatments for orphan inherited retinal diseases, announced an agreement to license its third preclinical program to address mutations in the NMNAT1 gene, which cause a specific form of Leber congenital amaurosis (LCA), from Massa